Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Oncaspar (Enzon Inc): Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Oncaspar (Enzon Inc) - General Information

Pegylated L-asparagine amidohydrolase from E. coli. Pegylation substantially (by a factor of 4) extends the protein half life.

 

Pharmacology of Oncaspar (Enzon Inc)

In a significant number of patients with acute leukemia, the malignant cells are dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase. Oncaspar exploits a metabolic defect in asparagine synthesis of some malignant cells.

 

Oncaspar (Enzon Inc) for patients

 

Oncaspar (Enzon Inc) Interactions

Unfavorable interactions of L-asparaginase with some antitumor agents have been demonstrated. 1 It is recommended, therefore, that ONCASPAR� be used in combination regimens only by physicians familiar with the benefits and risks of a given regimen. Depletion of serum proteins by ONCASPAR� may increase the toxicity of other drugs which are protein bound. Additionally, during the period of its inhibition of protein synthesis and cell replication, ONCASPAR� may interfere with the action of drugs such as methotrexate, which require cell replication for their lethal effects. ONCASPAR� may interfere with the enzymatic detoxification of other drugs, particularly in the liver. Physicians using a given treatment regimen should be thoroughly familiar with its benefits and risks.

Imbalances in coagulation factors have been noted with the use of ONCASPAR� predisposing to bleeding and/or thrombosis. Caution should be used when administering any concurrent anticoagulant therapy, such as coumadin, heparin, dipyridamole, aspirin, or non-steroidal anti-inflammatories.

 

Oncaspar (Enzon Inc) Contraindications

ONCASPAR� is contraindicated in patients with pancreatitis or a history of pancreatitis. ONCASPAR� is contraindicated in patients who have had significant hemorrhagic events associated with prior L-asparaginase therapy. ONCASPAR� is also contraindicated in patients who have had previous serious allergic reactions, such as generalized urticaria, bronchospasm, laryngeal edema, hypotension, or other unacceptable adverse reactions to ONCASPAR�.

 

Additional information about Oncaspar (Enzon Inc)

Oncaspar (Enzon Inc) Indication: For treatment of acute lymphoblastic leukemia Mechanism Of Action: Oncaspar (Enzon Inc), more effective than asparaginase, converts asparagine to aspartic acid and ammonia. It facilitates production of oxaloacetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and so the loss of exogenous sources of asparagine leads to cell death. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Pegaspargase Synonyms: L-asparagine amidohydrolase; Putative L-asparaginase precursor Drug Category: Antineoplastic Agents Drug Type: Biotech; Approved; Investigational Other Brand Names containing Pegaspargase: Oncaspar (Enzon Inc); Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Not Available Half Life: Not Available Dosage Forms of Oncaspar (Enzon Inc): Injection, solution IntramuscularInjection, solution Intravenous Chemical IUPAC Name: Pegylated E. coli L-asparagine amidohydrolase Chemical Formula: C1377H2208N382O442S17 Pegaspargase on Wikipedia: https://en.wikipedia.org/wiki/Pegaspargase Organisms Affected: Humans and other mammals